Aptinyx Inc. (NASDAQ:APTX – Get Rating) – William Blair issued their Q1 2024 EPS estimates for Aptinyx in a research note issued on Friday, March 31st. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Aptinyx's current full-year earnings is ($0.56) per share. William Blair also issued estimates for Aptinyx's Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS and Q4 2024 earnings at ($0.04) EPS.

A number of other research firms have also weighed in on APTX. SVB Leerink reissued a "market perform" rating and issued a $0.50 target price on shares of Aptinyx in a report on Wednesday, March 1st. HC Wainwright lowered shares of Aptinyx from a "buy" rating to a "neutral" rating in a report on Tuesday, March 7th. Finally, SVB Securities downgraded Aptinyx from an "outperform" rating to a "market perform" rating in a research report on Wednesday, March 1st. Eight research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $2.58.

Aptinyx Trading Down 6.5 %

APTX stock opened at $0.12 on Monday. The firm has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.34. Aptinyx has a fifty-two week low of $0.12 and a fifty-two week high of $2.87. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45. The firm has a market cap of $8.45 million, a PE ratio of -0.13 and a beta of 1.39.

Institutional Trading of Aptinyx

A number of institutional investors have recently bought and sold shares of APTX. Jane Street Group LLC lifted its position in shares of Aptinyx by 213.3% during the third quarter. Jane Street Group LLC now owns 105,771 shares of the company's stock worth $39,000 after purchasing an additional 72,006 shares during the last quarter. HBK Sorce Advisory LLC lifted its position in shares of Aptinyx by 100.0% during the fourth quarter. HBK Sorce Advisory LLC now owns 52,000 shares of the company's stock worth $53,000 after purchasing an additional 26,000 shares during the last quarter. Cetera Advisor Networks LLC bought a new stake in shares of Aptinyx during the first quarter worth $92,000. Renaissance Technologies LLC lifted its position in shares of Aptinyx by 14.3% during the fourth quarter. Renaissance Technologies LLC now owns 618,226 shares of the company's stock worth $176,000 after purchasing an additional 77,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Aptinyx by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 140,711 shares of the company's stock worth $320,000 after purchasing an additional 16,774 shares during the last quarter. 45.93% of the stock is currently owned by institutional investors.

Aptinyx Company Profile

(Get Rating)

Aptinyx Inc is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G.

Featured Stories

• Get a free copy of the StockNews.com research report on Aptinyx (APTX)
• MarketBeat Week in Review – 3/27 – 3/31
• What is a Gold IRA, and is it a Viable Investment?
• Is Braze Inc Ready To Rocket Higher?
• Mullen Automotive Makes Deliveries; Short-Squeeze Possible
• Can Frontline Maintain This Momentum?

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.